Implications for Treatment of the Metabolic Syndrome
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
|Official Title:||Implications for Treatment of the Metabolic Syndrome|
- Effect of atorvastatin 40 mg. o.d on muscle microvascular function and insulin sensitivity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- relationships between features of the metabolic syndrome, fitness, insulin sensitivity and microvascular function [ Time Frame: 6 months ] [ Designated as safety issue: No ]
|Study Start Date:||February 2006|
|Study Completion Date:||February 2008|
|Primary Completion Date:||February 2008 (Final data collection date for primary outcome measure)|
Active arm atorvastatin 40 mg. o.d.
40 m.g. o.d. tablets for 6 months
Placebo Comparator: 2
Placebo arm dummy pill
To characterise features of the metabolic syndrome, including body fat, insulin sensitivity, and liver fat together with muscle micorvascular blood flow.
To undertake a randomised controlled trial of atorvastatin 40 mg. o.d for 6 months to determine whether any of the above measures change with treatment.
No Contacts or Locations Provided